Semax Neuroprotective Research: Russian Nootropic ACTH(4-7) Analog

# Semax Neuroprotective Research: Russian Nootropic ACTH(4-7) Analog

For research purposes only. Not for human use. Semax is approved as a pharmaceutical in Russia but is not FDA-approved; the clinical findings below describe published research on the Russian medicinal product, not any use of research-grade material.

Introduction

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide built from the ACTH(4-7) fragment of adrenocorticotropic hormone with a C-terminal Pro-Gly-Pro (PGP) tail added for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it has been registered as a medicine in Russia since the 1990s for indications including ischemic stroke, cognitive disorders, and optic nerve disease — making it one of the few "nootropic" peptides with any regulatory approval anywhere, albeit not in the US or EU.

This article reviews the published, PubMed-indexed evidence: the neurotrophin mechanism work, the Russian clinical studies, and what an honest reader should make of the evidence quality. For pricing and supplier listings, see the Semax comparison page.

Origins and Development

The design rationale is documented in a 1997 retrospective by the developers spanning 15 years of work (PMID: 9173745): the ACTH(4-10) region carries the behavioral and cognitive activity of ACTH without its hormonal (corticotropic) activity, and the PGP extension prolongs the otherwise seconds-long half-life of the fragment. Early physiological work reported increased resistance to hypoxia in animal preparations as far back as 1992 (PMID: 1335426).

Unlike full-length ACTH, Semax does not meaningfully stimulate adrenal cortisol production — its actions are central, mediated through melanocortin-adjacent and neurotrophin pathways that remain incompletely characterized.

The BDNF Mechanism

The best-replicated mechanistic finding on Semax is upregulation of brain-derived neurotrophic factor (BDNF).

Dolotov et al., 2006 — Journal of Neurochemistry (PMID: 16635254). This study demonstrated two key facts. First, radiolabeled Semax binds specifically, reversibly, and calcium-dependently to rat basal forebrain membranes with a dissociation constant of about 2.4 nM — evidence of a discrete, saturable binding site. Second, intranasal Semax at 50 and 250 µg/kg raised BDNF protein levels in the basal forebrain within 3 hours, but not in the cerebellum — a regionally selective neurotrophin response.

Shadrina et al., 2010 — Journal of Molecular Neuroscience (PMID: 19662538). Follow-up work mapped the time course of NGF and BDNF gene expression across rat hippocampus, frontal cortex, and retina after Semax administration, showing rapid but regionally distinct neurotrophin transcription dynamics.

Neurotrophin receptor work, 2011 (PMID: 22295573) extended this to the trkA/trkB receptor axis, showing Semax and its PGP fragment alter expression of the neurotrophins and their receptors in rat tissue.

Because BDNF is a central regulator of synaptic plasticity, learning, and neuronal survival, this axis is the leading explanation for both the cognitive and neuroprotective claims.

Why Intranasal Delivery?

Nearly all Semax research — animal and clinical — uses intranasal administration, and the choice is mechanistic rather than cosmetic. Peptides of this size do not survive oral administration (gut proteases destroy them) and cross the blood-brain barrier poorly from systemic circulation. The nasal route exploits the olfactory and trigeminal nerve pathways, which offer a partially direct anatomical conduit from nasal mucosa to the central nervous system. The Dolotov binding study demonstrated the practical consequence: intranasal dosing at microgram-per-kilogram levels produced measurable BDNF elevation in deep forebrain structures within 3 hours (PMID: 16635254). Researchers evaluating published protocols should therefore treat route as a fixed feature of the evidence base — data from other routes essentially do not exist.

Transcriptomic and Anti-Inflammatory Findings

Beyond the neurotrophin axis, a body of genome-scale work from Russian groups has profiled what Semax does to the ischemic brain's gene-expression program. In rat middle-cerebral-artery-occlusion models, Semax and related ACTH-fragment peptides modulated expression of immune and inflammation-related gene networks in damaged brain tissue (Genes, 2023; PMID: 37510287), and a 2024 follow-up reported that ACTH-like peptides partially compensated the gene-expression profile disrupted by experimental ischemia within a day of stroke induction (Biomedicines, 2024; PMID: 39767736). These datasets suggest the peptide's neuroprotection is not a single-pathway effect but includes damping of post-ischemic neuroinflammation — consistent with the parent molecule's melanocortin heritage, since α-MSH-family peptides are broadly anti-inflammatory.

Stroke Research

Gusev et al., 2018 — Zhurnal Nevrologii i Psikhiatrii (PMID: 29798983). The most informative clinical dataset indexed on PubMed followed 110 patients recovering from ischemic stroke, divided into early (~89 days) and late (~214 days) rehabilitation groups, each subdivided into Semax-treated and untreated subgroups. The regimen was 6,000 µg/day intranasally in two 10-day courses separated by 20 days. Findings:

• •Semax administration raised plasma BDNF levels regardless of rehabilitation timing, and levels stayed elevated through the study period
• •Semax treatment and higher BDNF levels were associated with faster improvement and better final Barthel index (functional independence) scores
• •Early rehabilitation compounded the benefit — the BDNF–outcome correlation was modified by rehabilitation timing

Important caveats: this was an open-label design published in a Russian journal, not a double-blind placebo-controlled trial, and the primary readouts were functional scales plus a biomarker.

Preclinical stroke models support biological plausibility. A 2021 proteomic study (PMID: 34201112) confirmed protective changes in brain protein expression in a rat middle cerebral artery occlusion model, and a series of transcriptomic studies from the same research ecosystem (PMIDs: 37510287, 39767736) showed Semax modulates immune and inflammatory gene expression programs in ischemic rat brain.

Cognition, Stress, and Other Indications

• •Early-life stress model, 2021 — Neuropeptides (PMID: 33418449): Semax attenuated behavioral and neurochemical alterations following early-life stress in rodents.
• •Antidepressant-like activity, 2024 — European Journal of Pharmacology (PMID: 39442746): Semax and Melanotan II showed antidepressant-like and antistress effects in male mice, extending the melanocortin-behavior literature.
• •Glaucomatous optic neuropathy, 2001 (PMID: 11569188): a Russian ophthalmology study reported benefit in optic nerve disease — the basis of one of its Russian label indications.

Human cognition claims (improved attention and memory in healthy operators) trace largely to Soviet-era and 1990s Russian studies that predate modern trial registration and are difficult to audit; they should be treated as historical signals rather than established fact.

Evidence Quality Assessment

The honest summary: Semax has a real, replicated neurotrophin mechanism and consistent rodent neuroprotection data, but the human evidence is methodologically weaker than Western regulatory standards require — no registered double-blind placebo-controlled trials, publication concentrated in Russian-language journals, and endpoints vulnerable to bias in open-label designs.

Research Tools

Researchers comparing nootropic peptides can consult the Semax listing page for supplier pricing, use the peptide calculator for solution math, and read the Semax vs Selank comparison for a head-to-head of the two Russian regulatory peptides.

FAQ

Is Semax approved anywhere?

Yes — it is a registered pharmaceutical in Russia for stroke, cognitive disorders, and optic neuropathy. It has no FDA or EMA approval and is a research compound elsewhere.

What is the strongest evidence for Semax?

The BDNF mechanism: specific nanomolar binding in basal forebrain and rapid, region-selective BDNF elevation after intranasal dosing in rats (PMID: 16635254), replicated at the gene-expression level (PMID: 19662538).

Has Semax been tested in stroke patients?

Yes, in Russian clinical studies — most recently a 110-patient rehabilitation study showing higher plasma BDNF and better functional recovery scores (PMID: 29798983). These studies were not double-blind placebo-controlled trials.

Why the Pro-Gly-Pro tail?

Native ACTH(4-10) is degraded within seconds in plasma. The C-terminal PGP extension confers enough metabolic stability for intranasal delivery to produce central effects.

References

1. A nootropic adrenocorticotropin analog 4-10-Semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat. 1997. PMID: 9173745

2. Kaplan AY, et al. Increased resistance to hypoxia effected by the neuropeptide preparation SEMAX. Fiziol Cheloveka. 1992. PMID: 1335426

3. Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-6. PMID: 16635254

4. Shadrina M, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010. PMID: 19662538

5. The effect of Semax and its C-end peptide PGP on expression of the neurotrophins and their receptors in the rat brain. Mol Biol (Mosk). 2011. PMID: 22295573

6. Gusev EI, et al. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. PMID: 29798983

7. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia. Int J Mol Sci. 2021. PMID: 34201112

8. Semax attenuates behavioural and neurochemical alterations following early-life stress. Neuropeptides. 2021. PMID: 33418449

9. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II in male mice. Eur J Pharmacol. 2024. PMID: 39442746

10. Semax in the treatment of glaucomatous optic neuropathy. Vestn Oftalmol. 2001. PMID: 11569188

---

This article is for informational and research purposes only. Semax research materials are not for human consumption.